Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT03403686

Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)

Sponsor: University of Alabama at Birmingham

View on ClinicalTrials.gov

Summary

Results from large clinical trials demonstrate a strong association between lipid abnormalities and progression of the most common microvascular complication, diabetic retinopathy (DR). We found that activation of a master regulator of cholesterol metabolism, the nuclear hormone receptors liver X receptors (LXRα/LXRβ), prevents DR in rodent models. In this application, we seek to understand the mechanisms responsible for the beneficial effects of LXR agonists on retina and on bone marrow (BM) to preserve the function of reparative cells while reducing inflammatory cell.

Official title: LXR as a Novel Therapeutic Target in DR

Key Details

Gender

All

Age Range

21 Years - 98 Years

Study Type

OBSERVATIONAL

Enrollment

104

Start Date

2018-01-11

Completion Date

2026-12-31

Last Updated

2025-09-17

Healthy Volunteers

Yes

Interventions

BIOLOGICAL

blood draw

Blood sample will be obtained and CD34+ cells will be isolated for functional testing.

Locations (1)

University of Alabama at Birmingham

Birmingham, Alabama, United States